AstraZeneca Acquires EsoBiotec for $1B
This is a news story, published by Yahoo Finance, that relates primarily to AstraZeneca news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
biotechnology company EsoBiotec. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Gracell Biotechnologies news, cell therapies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cell therapy capabilitiesReuters
•Health
Health
AstraZeneca to buy EsoBiotec for up to $1 billion

83% Informative
AstraZeneca has been actively expanding its cell therapy capabilities.
EsoBiotec has technology that can genetically modify immune cells directly inside the body, allowing for transformative cell therapy treatments in just minutes instead of the current process which can take weeks .
The transaction is expected to close in the second quarter of 2025 .
VR Score
92
Informative language
97
Neutral language
76
Article tone
formal
Language
English
Language complexity
86
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links